Elisa Lucchini
Overview
Explore the profile of Elisa Lucchini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ragaini S, Galli A, Genuardi E, Gandossini M, Alessandria B, Civita A, et al.
Blood Adv
. 2025 Jan;
PMID: 39808795
Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell lymphoma (MCL) remains unclear. Here, we report a comprehensive NGS-based analysis...
2.
Martelli M, Ceriani L, Ciccone G, Ricardi U, Kriachok I, Botto B, et al.
J Clin Oncol
. 2024 Aug;
42(34):4071-4083.
PMID: 39159403
Purpose: The role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. Methods: The IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can...
3.
Cavallo F, Clerico M, Lucchini E, Castiglione A, Re A, Zilioli V, et al.
Br J Haematol
. 2024 Jun;
205(4):1404-1410.
PMID: 38938122
Mantle cell lymphoma (MCL) is a rare lymphoproliferative neoplasm considered incurable, with a median survival of 3-5 years. In recent years, Bruton's tyrosine kinase inhibitors (BTKi) have been introduced, demonstrating...
4.
Herling M, Dearden C, Zaja F, El-Sharkawi D, Ding W, Bellido M, et al.
Blood Adv
. 2024 Jan;
8(4):842-845.
PMID: 38190628
No abstract available.
5.
Zaja F, Lucchini E, Poiani M, Sbisa E, Mohamed S, De Bellis E, et al.
Am J Hematol
. 2023 Nov;
99(1):E29-E31.
PMID: 38032813
No abstract available.
6.
Ferrero S, Grimaldi D, Arrigoni E, Pironti M, Zaccaria G, Alessandria B, et al.
Blood Adv
. 2023 Apr;
7(14):3764-3774.
PMID: 37058477
In the Fondazione Italiana Linfomi MCL0208 phase 3 trial, lenalidomide maintenance (LEN) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL) improved progression-free survival (PFS) vs observation (OBS)....
7.
Mohamed S, Lucchini E, Sirianni F, Porrazzo M, Ballotta L, Ballerini M, et al.
Front Oncol
. 2023 Mar;
13:1133348.
PMID: 36923438
messenger RNA (mRNA)-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccines such as BNT162b2 became available in late 2020, but hematological malignancy patients (HM pts) were not evaluated in initial registration...
8.
Napolitano M, Vianelli N, Ghiotto L, Cantoni S, Carli G, Carpenedo M, et al.
Mediterr J Hematol Infect Dis
. 2023 Mar;
15(1):e2023019.
PMID: 36908864
Background: Two thrombopoietin receptor agonists (TPO-RA), romiplostim and eltrombopag, are currently widely adopted as second-line ITP therapy even in the absence of robust evidence on their comparative advantages over rituximab...
9.
Argnani L, Broccoli A, Pellegrini C, Fabbri A, Puccini B, Bruna R, et al.
Hemasphere
. 2022 Nov;
6(12):e798.
PMID: 36398133
After FDA and EMA approval of the regimen containing polatuzumab vedotin plus rituximab and bendamustine (PolaBR), eligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients in Italy were granted early access...
10.
Ballotta L, Simonetti O, DAgaro P, Segat L, Koncan R, Martinez-Orellana P, et al.
Front Oncol
. 2022 Oct;
12:945060.
PMID: 36249044
Post-coronavirus disease 2019 (post-COVID-19) condition, previously referred to as long COVID, includes a post-acute syndrome defined by the presence of non-specific symptoms occurring usually 3 months from the onset of...